poisar

Stocks · News reference

HC Wainwright & Co. Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $85

Benzinga Newsdesk

HC Wainwright & Co. analyst Joseph Pantginis maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and raises the price target from $57 to $85.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

RIGL
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate

    Arvinas announced the first patient dosing in a Phase 1/2 clinical trial of ARV-6723, an oral PROTAC designed to degrade HPK1 for advanced solid tumors. The drug is Arvinas' first immuno-oncology candidate and the first HPK1 PROTAC degrader to enter clinical trials in the US. Preclinical data showed potent HPK1 degradation, enhanced immune activity, and antitumor effects as monotherapy and in combination with anti-PD-1 therapy, including activity in anti-PD-1-resistant models.

    ARVNPFERIGL
  2. Na

    Thérapeutique Knight annonce l’approbation réglementaire de TAVALISSE® en Colombie

    Knight Therapeutics Inc. (TSX: GUD) announced regulatory approval from Colombia's INVIMA for TAVALISSE® (fostamatinib disodium heptahydrate) to treat adult patients with chronic immune thrombocytopenia (ITP). The approval marks a significant milestone in Knight's Latin American expansion strategy following its 2022 licensing agreement with Rigel Pharmaceuticals. The company plans to launch TAVALISSE in Colombia in H1 2027, following launches in Mexico (May 2026) and Brazil (Q4 2026).

    RIGL
  3. Knight Therapeutics Inc.

    Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Colombia

    Knight Therapeutics announced that it received regulatory approval from Colombia's health authority (INVIMA) for TAVALISSE (fostamatinib disodium hexahydrate) to treat adult patients with chronic immune thrombocytopenia (ITP). The company plans to launch the drug in Colombia in the first half of 2027, following its May 2026 launch in Mexico and an expected Q4 2026 launch in Brazil.

    RIGL